Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Take action
Record your position on this measure.
Create an account to record your position, submit testimony, or contact your legislator.
Progress
Where this bill stands in the legislative process.
- Introduced
- Passed Senate
- Passed House
- To President
- Became Law
Overview
This bill, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, would allow Medicare to cover and pay for multi-cancer early detection screening tests starting in 2028. These tests, which must be FDA-cleared or approved and analyze multiple cancer types, would be limited to individuals under 68 years old in 2028 (increasing annually) and to one test every 11 months. The bill also establishes payment amounts and standards for these screenings.
Key provisions
- Medicare coverage and payment for multi-cancer early detection screening tests starting in 2028.
- Tests must be FDA-cleared or approved and analyze multiple cancer types.
- Coverage is limited to individuals under 68 years old in 2028, increasing annually.
- Individuals can receive only one test every 11 months.
- Payment amounts are linked to existing multi-target stool screening DNA tests and will be adjusted over time.
- The Secretary will use the National Coverage Determination (NCD) process for new tests.
- A grade A or B recommendation from the US Preventive Services Task Force will exempt the bill’s limitations.
- The bill makes changes to existing Medicare regulations to accommodate these new screenings.
Who is affected
- Medicare beneficiaries
- Healthcare providers offering multi-cancer early detection screening tests
- Pharmaceutical companies developing these tests
Bill text
Read the latest version inline or switch to a previous version.
Text extraction is in progress. View the official source.
Sponsors
Official sponsors from legislative records.
69 on record
Primary sponsor
Cosponsors
Arguments
Reasons offered for and against this legislation.
Arguments in favor
No arguments in favor have been submitted.
Submit yoursArguments opposed
No arguments opposed have been submitted.
Submit yours